TMDX — TransMedics Income Statement
0.000.00%
Last trade - 00:00- $3.16bn
- $3.34bn
- $441.54m
- 78
- 13
- 72
- 54
Annual income statement for TransMedics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 53 W | 52 W | 52 W | 52 W | 52 W |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 25.6 | 30.3 | 93.5 | 242 | 442 |
| Cost of Revenue | |||||
| Gross Profit | 16.6 | 21.2 | 65.3 | 154 | 262 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 52 | 69.7 | 124 | 270 | 404 |
| Operating Profit | -26.4 | -39.4 | -30.8 | -28.7 | 37.5 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -28.7 | -44.2 | -36.2 | -26.7 | 35.8 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -28.7 | -44.2 | -36.2 | -25 | 35.5 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -28.7 | -44.2 | -36.2 | -25 | 35.5 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -28.7 | -44.2 | -36.2 | -25 | 35.5 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.16 | -1.6 | -1.24 | 0.107 | 1.01 |